TG Therapeutics Inc (FRA:NKB2)
€ 15.684 0.162 (1.04%) Market Cap: 2.54 Bil Enterprise Value: 2.45 Bil PE Ratio: 80.14 PB Ratio: 17.02 GF Score: 73/100

TG Therapeutics Inc at B Riley Neuro & Ophthalmology Conference (Virtual) Transcript

Apr 28, 2022 / 04:30PM GMT
Release Date Price: €6.19 (-1.87%)
Mayank Mamtani
B. Riley Securities, Inc. - Analyst

Good afternoon, everyone, and good morning for folks here on the West Coast. So for our next fireside chat, we are delighted to welcome Mike Weiss, the CEO of TG Therapeutics.

Thanks, Mike, for being here today. I know you have a lot going on, but obviously, the focus for today would be ublituximab in RMS.

But obviously, there is a lot that has changed in the story just in the past two quarters. So maybe just help us understand how should we think about TG, where we stand, and then we will get into sort of very steady progresses in the coming months.

Mike Weiss
TG Therapeutics, Inc. - Chairman, President, & CEO

Yeah, sure. Great to see you and thanks for having us. So yeah, I think I heard you say a lot of things have changed in the last two quarters. I think most of it has happened in the last two weeks. So it's been a pretty aggressive change of course.

Unfortunately, as you know and sure most of the viewers know, we ran into a bit of a challenge for our CLL application,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot